ABOUT US

20/20 OptimEyes Technologies is transforming how medicines are delivered at the body’s mucosal surfaces. Our mission is to make treatments simpler, safer, and more effective through our mucoadhesive nanoparticle (MNP) platform, enabling sustained, localized delivery that improves therapeutic outcomes and patient quality of life.  Led by a talented team and experienced key advisors, we are de-risking our platform through our lead indication of glaucoma, while developing a pipeline of products in respiratory, urology, oncology and women's health applications.

Our business strategy is dual pronged. We are working on internal product development utilizing existing therapeutics, such as latanoprost for glaucoma. We are also interested in external collaborations, using strategic partnerships to examine novel therapeutics with our formulation. These are therapeutics that could benefit from lower doses, controlled release, higher solubility or a reduced dosing regimen. We are able to support the in vitro and in vivo feasibility and optimization studies for our partners as required.